OncoHost

05/27/2026

We’re excited to connect with you at the upcoming Annual Meeting in Chicago!

📍 Visit Us at Booth #28148
Stop by to meet our leadership team and explore how our proteomics and AI-powered platform is driving the next era of precision oncology.

05/11/2026

Our team is gearing up for ASCO 2026!
Stop by our booth #28148 or reach out to [email protected] to set up a meeting!

05/04/2026

May is National Cancer Research Month, an initiative led by the American Association for Cancer Research (AACR) to highlight the critical importance of life-saving research for the millions of people worldwide affected by cancer.

04/24/2026

🔬 It’s Medical Laboratory Professionals Week!

Here’s to the brilliant minds working behind the scenes to power precision medicine and patient care.
Thank you to our incredible lab professionals - Jim Fuller, Amir Gelman, Michael Hoxie & Macalla Tate! Your dedication to accuracy and excellence is what enables innovation to reach each patient.

04/23/2026

Our Chief Commercial Officer, Chris Dingman, took the stage to present our latest poster, highlighting the role of biological aging in predicting outcomes. The work underscores our ongoing commitment to equipping physicians with tools that bring greater clarity to complex clinical choices.

Take a closer look at the science driving the future of personalized cancer care.

04/19/2026

Attending AACR?
Don’t miss our poster presentation:
“Proteomic aging biomarkers predict survival in immunotherapy-treated tumors.”

🗓 Monday, April 20, 2026
🕘 9:00 AM – 12:00 PM (PDT)

Stop by to explore how proteomic insights are shaping the future of immunotherapy outcomes.

04/15/2026

We're proud to announce the acceptance of our abstract for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place next week in San Diego!

This research highlights the impact of biological aging as a predictive factor for immunotherapy outcomes across multiple tumor types, including , SCLC, renal cell carcinoma (RCC), and melanoma.

Read our news release here:

PR Newswire’s news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.

04/13/2026

Our team is heading to this weekend! ✈️🔬

We’re looking forward to connecting with the global oncology community, exchanging insights, and driving the future of precision medicine through innovative biomarker-driven solutions.

See you there!

04/01/2026

Thank you MLO - Medical Laboratory Observer for spotlighting our recent publication in the Journal of Pharmaceutical and Biomedical Analysis (JPBA)!

This study introduces a validated computational method to harmonize serum and plasma proteomic datasets, overcoming longstanding analytical barriers and enabling more comprehensive biomarker research across diverse cohorts.

Read the coverage 👇

This recent study introduces a validated computational method to harmonize serum and plasma proteomic datasets, overcoming longstanding analytical barriers and enabling more comprehensi...

03/24/2026

🏆We’re proud to share that OncoHost has been named a winner in the 2026 Artificial Intelligence Excellence Awards by the Business Intelligence Group, taking top recognition in the Health category!

This award underscores what truly matters: real-world impact.

With PROphet®, our machine learning–based proteomics platform, we enable oncologists to make more precise, data-driven treatment decisions by decoding the patient’s systemic response—translating AI from promise into real-world clinical impact. 🚀

We’re grateful to the Business Intelligence Group for this recognition, and even more so to the teams across OncoHost who continue to push the boundaries of what’s possible in precision oncology.

https://prn.to/4d2Qfxe

/PRNewswire/ -- OncoHost, an AI-driven precision oncology company transforming clinical decision-making through proteomic analysis and machine learning, today...

03/23/2026

🚀 Redefining Precision Oncology with PROphet®
At OncoHost, we're not just keeping pace with innovation — we're setting the standard. The PROphet® platform is our flagship host-response profiling technology, designed to help oncologists make smarter, faster, and more personalized treatment decisions.

By analyzing proteomic patterns in patients' blood, PROphet® predicts therapeutic outcomes with unprecedented accuracy — giving physicians a powerful edge in managing complex cancers.

✅ Actionable insights
✅ AI-powered predictions
✅ Personalized patient care

The future of oncology isn’t just personalized. It’s precisely guided.
Learn more about how PROphet® is changing the game 👉

Explore OncoHost's home for cutting-edge precision oncology solutions, driving advancements in cancer care and personalized treatment strategies.